Clinical Trials · NCT01578239
A Study Comparing Treatment With 177Lu-DOTA0-Tyr3-Octreotate to Octreotide LAR in Patients With Inoperable, Progressive, Somatostatin Receptor Positive Midgut Carcinoid Tumours
- Phase
- Phase 3
- Recruitment status
- Completed
- Sponsor
- Advanced Accelerator Applications
- Enrollment
- 231
- Start date
- Sep 2012
- Locations
- 39 sites, 8 countries
- Primary endpoint
- Progression Free Survival (PFS)